After BWX Technologies had its best day on record, Cathie Wood's ARK Invest shed shares of the nuclear play across two of its flagship funds.

The sale included 2,639 shares by the ARK Innovation exchange-traded fund, which is concentrated in so-called disruptive technology and dominated by names such as Crispr Therapeutics and Advanced Micro Devices. As of Friday, ARK Innovation held 303,133 BWX shares valued at roughly $69.8 million, or 1.17% of the portfolio by weight.

The second fund to sell was the ARK Autonomous Technology & Robotics ETF, which shed 839 shares. BWX is the fund's 18th-largest holding by weight, comprising 2.08% of the portfolio. The fund holds 173,687 shares, which were valued at nearly $40 million on Friday.

BWX has been a notably strong performer this year, surging 34% against a 0.4% decline for the S&P 500. The stock more than doubled in 2025, driven higher by backlog growth and contract wins with both government and commercial clients. The company counts the Defense Department and NASA among its largest customers.

BWX closed at a record high of $231.78 on April 8, and it extended its gains into the following session, when shares reached $237.90, their highest level on record.

Earlier this week, BWX notified regulators of its intent to license a new uranium enrichment plant adjacent to its existing nuclear fuel site in Tennessee. The company reports first-quarter earnings on May 4.

Inside Scoop is a regular Barron's feature covering stock transactions by corporate executives and board members -- so-called insiders -- as well as large shareholders, politicians, and other prominent figures. Due to their insider status, these investors are required to disclose stock trades with the Securities and Exchange Commission or other regulatory groups.